AR
AVDL

Advisory Research’s Avadel Pharmaceuticals AVDL Stock Holding History

Advisory Research’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-104,654
Closed -$1.48M – 176
2023
Q4 		$1.48M Sell
104,654
-96,455
-48% -$1.13M 0.23% 120
2023
Q3 		$2.07M Sell
201,109
-68,968
-26% -$924K 0.29% 98
2023
Q2 		$4.45M Buy
+270,077
New +$3.51M 0.57% 41

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Advisory Research's AVDL Position: Q1 2024 in Review

Advisory Research sold out of Avadel Pharmaceuticals (AVDL) in Q1 2024, closing a stake of 104,654 shares — an estimated $1.48M sold.

Advisory Research first reported a position in AVDL in Q2 2023 and held it in 3 quarters. The position peaked at $4.45M in Q2 2023. 127 funds tracked by Wall St. Rank hold AVDL as of Q1 2024.

  • Advisory Research reported no remaining Avadel Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Advisory Research sold 104,654 Avadel Pharmaceuticals shares in Q1 2024, an estimated $1.48M.
  • Advisory Research first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Advisory Research's Avadel Pharmaceuticals position peaked at $4.45M in Q2 2023.
  • 127 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.